Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

This study has been completed.
Information provided by (Responsible Party):
Deciphera Pharmaceuticals LLC Identifier:
First received: January 21, 2009
Last updated: July 16, 2014
Last verified: July 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):